Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$99.26

-0.63 (-0.63%)

14:04
10/10/16
10/10
14:04
10/10/16
14:04

TESARO may fail to secure broad approval for niraparib, Feuerstein says

With TESARO soaring Monday after reporting positive Phase 3 data on its ovarian cancer therapy niraparib, TheStreet's Adam Feuerstein cautions that "positive data does not eliminate all risks" for the company. The "lingering controversy" surrounding TESARO, argues Feuerstein, is whether it can secure regulatory approval for broad use of niraparib. The company's $6B market cap indicates investors are betting on broad approval, but Feuerstein warns that one-third, or even two-thirds, of the 20,000 ovarian cancer patients that TESARO is hoping to treat could be excluded if regulators "take a more cautious approach" on the drug. He highlights that certain patient groups enrolled in TESARO's study showed just a 3.1/5.4 month delay in disease progression, which would appear to miss the FDA's guidelines seeking a minimum progression delay of six months. Reference Link

  • 06

    Nov

  • 11

    Jan

TSRO Tesaro
$99.26

-0.63 (-0.63%)

10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Strong Buy
TESARO price target raised to $120 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 fter the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating.
10/10/16
FBCO
10/10/16
NO CHANGE
Target $122
FBCO
Outperform
TESARO price target raised to $122 on Niraparib data at Credit Suisse
Credit Suisse analyst Alethia Young raised TESARO's price target to $122 from $90 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The analyst thinks niraparib has broad effects across the 2nd line ovarian population and would expect the label is broad. Young has an Outperform ratting n TESARO shares.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Outperform
TESARO price target raised to $120 from $105 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating
10/10/16
RBCM
10/10/16
NO CHANGE
RBCM
TESARO price target raised to $128 from $122 at RBC Capital
RBC Capital analyst Adnan Butt raised his price target on TESARO after ovarian cancer patients taking the company's Niraparib drug responded better than expected. Butt said that the drug benefited the patients regardless of BRCA or HRD biomarker status. He keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

AZRX

AzurRx BioPharma

$3.51

-0.04 (-1.13%)

15:54
04/28/17
04/28
15:54
04/28/17
15:54
Hot Stocks
Breaking Hot Stocks news story on AzurRx BioPharma »

Matthew Balk reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMF

OneMain Holdings

$23.36

-1.26 (-5.12%)

15:51
04/28/17
04/28
15:51
04/28/17
15:51
Options
Opening action in OneMain Holdings puts as shares drop »

Opening action in OneMain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 25

    May

CHFC

Chemical Financial

$47.97

-0.79 (-1.62%)

15:50
04/28/17
04/28
15:50
04/28/17
15:50
Upgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

BOFI

BofI Holding

$24.76

0.52 (2.15%)

15:46
04/28/17
04/28
15:46
04/28/17
15:46
Options
BofI Holding call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 30

    May

B

Barnes Group

$55.35

2.1 (3.94%)

15:43
04/28/17
04/28
15:43
04/28/17
15:43
Downgrade
Barnes Group rating change  »

Barnes Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

ADI

Analog Devices

$77.85

-0.13 (-0.17%)

15:36
04/28/17
04/28
15:36
04/28/17
15:36
Options
Analog Devices put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

MDXG

MiMedx

$11.40

0.3 (2.70%)

15:32
04/28/17
04/28
15:32
04/28/17
15:32
Recommendations
MiMedx analyst commentary  »

MiMedx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 06

    Jun

GST

Gastar Exploration

$1.31

0.01 (0.77%)

15:30
04/28/17
04/28
15:30
04/28/17
15:30
Conference/Events
Gastar Exploration to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 05

    May

CLVS

Clovis

$58.21

-0.43 (-0.73%)

15:26
04/28/17
04/28
15:26
04/28/17
15:26
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

$NSD

NASDAQ Market Internals

15:17
04/28/17
04/28
15:17
04/28/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIG

Fortress

$8.04

0.005 (0.06%)

, SFTBF

SoftBank

$75.60

0.71 (0.95%)

15:17
04/28/17
04/28
15:17
04/28/17
15:17
Periodicals
Fortress exploring sale of Logan Circle bond fund unit, Reuters says »

Fortress Investment Group…

FIG

Fortress

$8.04

0.005 (0.06%)

SFTBF

SoftBank

$75.60

0.71 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
04/28/17
04/28
15:16
04/28/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
04/28/17
04/28
15:15
04/28/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CAG

Conagra Brands

$38.82

0.005 (0.01%)

15:11
04/28/17
04/28
15:11
04/28/17
15:11
Options
Downside put buyer in Conagra Foods »

Downside put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAH

Cardinal Health

$72.36

-0.78 (-1.07%)

15:10
04/28/17
04/28
15:10
04/28/17
15:10
Initiation
Cardinal Health initiated  »

Cardinal Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

FIG

Fortress

$8.04

0.01 (0.12%)

15:04
04/28/17
04/28
15:04
04/28/17
15:04
Periodicals
Breaking Periodicals news story on Fortress »

Fortress exploring sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$9.06

0.03 (0.33%)

15:01
04/28/17
04/28
15:01
04/28/17
15:01
Options
Sprint calls active ahead of earnings next week »

Sprint calls active ahead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

GME

GameStop

$22.80

-0.3 (-1.30%)

14:56
04/28/17
04/28
14:56
04/28/17
14:56
Options
GameStop put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 31

    May

BSX

Boston Scientific

$26.43

0.25 (0.95%)

14:55
04/28/17
04/28
14:55
04/28/17
14:55
Recommendations
Boston Scientific analyst commentary  »

Boston Scientific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 07

    Jun

  • 27

    Jun

TKPYY

Takeda Pharmaceutical Co. Ltd.

$23.98

0.05 (0.21%)

14:51
04/28/17
04/28
14:51
04/28/17
14:51
Hot Stocks
FDA grants accelerated approval to Takeda's brigatinib »

On April 28, 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$39.76

-0.34 (-0.85%)

14:48
04/28/17
04/28
14:48
04/28/17
14:48
Conference/Events
The Progressive Corporation to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVO

Cenveo

$4.39

0.095 (2.21%)

14:48
04/28/17
04/28
14:48
04/28/17
14:48
Hot Stocks
Breaking Hot Stocks news story on Cenveo »

Nathu Ram Puri reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

BMY

Bristol-Myers

$56.01

0.34 (0.61%)

14:42
04/28/17
04/28
14:42
04/28/17
14:42
Hot Stocks
Bristol-Myers announces European Commission approval of Opdivo »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 06

    Jun

TAP

Molson Coors

$95.84

0.06 (0.06%)

14:41
04/28/17
04/28
14:41
04/28/17
14:41
Conference/Events
Molson Coors to hold an earnings follow-up conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

IWM

iShares Trust Russell 2000 Index Fund

$139.37

-1.58 (-1.12%)

, RUT

Russell 2000 Index

14:40
04/28/17
04/28
14:40
04/28/17
14:40
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$139.37

-1.58 (-1.12%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.